Thermo Fisher to Expand in Bedford and Chelmsford, Spend $600M Worldwide

Thermo Fisher has announced more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions.

With these investments, the company expects to create more than 1,500 new jobs across 11 manufacturing sites in the Americas, Europe and Asia. Specific investments include expanding its state-of-the-art resin manufacturing site in Bedford and opening a new 85,000-square-foot manufacturing facility in Chelmsford. Together, these sites will reinforce Thermo Fisher’s purification network that specializes in the production of process-scale chromatography resins for a variety of applications, including vaccines and gene therapies.

Other investments include expanding capacity for its single-use technologies business at sites in Logan, Utah; Millersburg, Pa.; Cramlington, U.K.; Singapore and Suzhou, China.  Additional investment at its Santa Clara, Calif. site will expand bioprocessing equipment and automation capacity. (Source: Thermo Fisher Website, 10 March, 2021)